Wealthfront Advisers LLC Sells 3,899 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Wealthfront Advisers LLC reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,721 shares of the biopharmaceutical company's stock after selling 3,899 shares during the period. Wealthfront Advisers LLC's holdings in Alnylam Pharmaceuticals were worth $2,355,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Signaturefd LLC increased its holdings in Alnylam Pharmaceuticals by 7.0% in the first quarter. Signaturefd LLC now owns 1,755 shares of the biopharmaceutical company's stock valued at $474,000 after buying an additional 115 shares in the last quarter. CWM LLC boosted its position in Alnylam Pharmaceuticals by 26.3% during the first quarter. CWM LLC now owns 16,664 shares of the biopharmaceutical company's stock worth $4,500,000 after acquiring an additional 3,473 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 673.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company's stock valued at $3,684,000 after purchasing an additional 11,881 shares during the last quarter. Ballentine Partners LLC boosted its holdings in Alnylam Pharmaceuticals by 3.3% in the 1st quarter. Ballentine Partners LLC now owns 1,625 shares of the biopharmaceutical company's stock valued at $439,000 after purchasing an additional 52 shares during the last quarter. Finally, Xponance Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 3.1% in the 1st quarter. Xponance Inc. now owns 23,157 shares of the biopharmaceutical company's stock worth $6,253,000 after acquiring an additional 701 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. This represents a 28.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ALNY. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a report on Monday, June 30th. BMO Capital Markets upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 24th. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $346.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $4.16 during mid-day trading on Friday, hitting $320.53. The stock had a trading volume of 581,322 shares, compared to its average volume of 852,386. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $333.70. The firm has a market cap of $41.79 billion, a PE ratio of -153.36 and a beta of 0.23. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company's 50-day simple moving average is $306.46 and its 200-day simple moving average is $271.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same period in the previous year, the company earned ($0.16) EPS. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.